Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577425 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6577459 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL98283 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6577351 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL11834546 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL4957180 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6579084 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL1772170 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL96647 | 0.98 | MAOA (0.52) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL97266 | 0.91 | HDAC3 (0.50) | MAPTRXFP1SIGMAR1MAOAMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0856007-B1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | MAPT 4254/4885RXFP1 175/4885SIGMAR1 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.